Avilar Therapeutics
Biotechnology, 400 Totten Pond Rd Ste 110, Waltham, Massachusetts, 02451, United States, 11-50 Employees
Phone Number: 17*********
Who is AVILAR THERAPEUTICS
Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar deve...
Read More
-
Headquarters: 400 Totten Pond Rd Ste 110, Waltham, Massachusetts, 02451, United States
-
Date Founded: 2020
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from AVILAR THERAPEUTICS
Avilar Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Avilar Therapeutics
Answer: Avilar Therapeutics's headquarters are located at 400 Totten Pond Rd Ste 110, Waltham, Massachusetts, 02451, United States
Answer: Avilar Therapeutics's phone number is 17*********
Answer: Avilar Therapeutics's official website is https://avilar-tx.com
Answer: Avilar Therapeutics's revenue is $1 Million to $5 Million
Answer: Avilar Therapeutics's SIC: 8731
Answer: Avilar Therapeutics's NAICS: 541714
Answer: Avilar Therapeutics has 11-50 employees
Answer: Avilar Therapeutics is in Biotechnology
Answer: Avilar Therapeutics contact info: Phone number: 17********* Website: https://avilar-tx.com
Answer: Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month